drugset / Trial / NCT00959036

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

NCT00959036

Phase 1/2 Completed 252 enrolled Ablynx, a Sanofi company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.

Timeline

Start
2009-09
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject OZORALIZUMAB Monoclonal antibody 10 mg
Subject OZORALIZUMAB Monoclonal antibody 30 mg
Subject OZORALIZUMAB Monoclonal antibody 80 mg
Background Methotrexate Small molecule

Indications